Ideaya Biosciences Stock Alpha and Beta Analysis
| IDYA Stock | USD 31.52 0.38 1.19% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ideaya Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ideaya Biosciences over a specified time horizon. Remember, high Ideaya Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ideaya Biosciences' market risk premium analysis include:
Beta 0.83 | Alpha 0.0258 | Risk 2.59 | Sharpe Ratio 0.0004 | Expected Return 0.0009 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Ideaya Biosciences Analysis, Ideaya Biosciences Valuation, Ideaya Biosciences Correlation, Ideaya Biosciences Hype Analysis, Ideaya Biosciences Volatility, Ideaya Biosciences Price History and analyze Ideaya Biosciences Performance. Ideaya Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ideaya Biosciences market risk premium is the additional return an investor will receive from holding Ideaya Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ideaya Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ideaya Biosciences' performance over market.| α | 0.03 | β | 0.83 |
Ideaya Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Ideaya Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Ideaya Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Ideaya Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Ideaya Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ideaya Biosciences shares will generate the highest return on investment. By understating and applying Ideaya Biosciences stock market price indicators, traders can identify Ideaya Biosciences position entry and exit signals to maximize returns.
Ideaya Biosciences Return and Market Media
The median price of Ideaya Biosciences for the period between Fri, Nov 14, 2025 and Thu, Feb 12, 2026 is 34.23 with a coefficient of variation of 4.77. The daily time series for the period is distributed with a sample standard deviation of 1.63, arithmetic mean of 34.23, and mean deviation of 1.32. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Will IDEAYA Biosciences Inc. stock see PE expansion - Market Risk Summary Technical Buy Zone Confirmations - newser.com | 11/19/2025 |
2 | Disposition of 1672 shares by Ruiz Briseno Andres of Ideaya Biosciences at 34.0 subject to Rule 16b-3 | 11/21/2025 |
3 | Is GSKs Exit and IDE034s FDA Green Light Reframing the Investment Case For IDEAYA Biosciences | 12/09/2025 |
4 | Avoiding Lag Real-Time Signals in Movement - Stock Traders Daily | 12/31/2025 |
5 | Disposition of 29761 shares by Yujiro Hata of Ideaya Biosciences at 43.4775 subject to Rule 16b-3 | 01/02/2026 |
6 | IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference | 01/05/2026 |
7 | Why IDEAYA Biosciences Inc. stock remains on buy lists - July 2025 Short Interest Smart Money Movement Tracker - ulpravda.ru | 01/08/2026 |
8 | Why IDEAYA Biosciences Stock Is Breaking Out Now - TipRanks | 01/14/2026 |
9 | Has IDEAYA Biosciences Run Too Far After Strong MultiYear Share Price Gains | 01/21/2026 |
10 | Disposition of 500 shares by Throne Jason of Ideaya Biosciences at 30.0 subject to Rule 16b-3 | 01/26/2026 |
11 | IDEAYA Biosciences, Inc. Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat | 01/27/2026 |
12 | A Look At IDEAYA Biosciences Valuation After Recent Share Price Pullback | 02/02/2026 |
13 | IDEAYA Biosciences, Inc. IDYA Shares Acquired by Candriam S.C.A. - MarketBeat | 02/10/2026 |
About Ideaya Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ideaya or other stocks. Alpha measures the amount that position in Ideaya Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2025 | 2026 (projected) | Current Ratio | 19.65 | 13.47 | 9.63 | Net Debt To EBITDA | 1.41 | 0.22 | 0.21 |
Ideaya Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Ideaya Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ideaya Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ideaya Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ideaya Biosciences. Please utilize our Beneish M Score to check the likelihood of Ideaya Biosciences' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ideaya Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Ideaya Biosciences Analysis, Ideaya Biosciences Valuation, Ideaya Biosciences Correlation, Ideaya Biosciences Hype Analysis, Ideaya Biosciences Volatility, Ideaya Biosciences Price History and analyze Ideaya Biosciences Performance. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Ideaya Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.